These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12019103)

  • 1. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
    Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
    Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
    Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
    Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
    Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
    Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
    Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
    Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
    Nikonenko BV; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
    Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
    J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
    Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.